Eisai Files for Earlier use of Halaven® (Eribulin) for the Treatment of
Metastatic Breast Cancer
HATFIELD, England, May 7, 2013
HATFIELD, England, May 7, 2013 /PRNewswire/ --
Eisai today announced that it has filed a Type II Variation application with
the European Medicines Agency (EMA) for Halaven (eribulin), requesting an
indication extension to include treatment of earlier line metastatic breast
cancer (MBC) patients.
Eribulin is the first and only single-agent therapy proven to significantly
extend overall survival after two prior lines of MBC therapy when compared to
other single-agent therapies. Results from a pivotal Phase III study (EMBRACE)
demonstrated a statistically significant median overall survival benefit for
women treated with eribulin compared with a single-agent treatment of
physician's choice (TPC). ^
Eribulin is currently indicated in Europe for the treatment of women with
locally advanced or MBC who have previously received at least two
chemotherapeutic regimens. Prior therapy should have included an anthracycline
and a taxane unless women were not suitable for these treatments. ^[ ^2]
Eisai is dedicated to discovering, developing and producing innovative
oncology therapies that can make a difference and impact the lives of women
and their families. This passion for people is part of Eisai's human health
care (hhc) mission, which strives for better understanding of the needs of
patients and their families to increase the benefits health care provides.
Notes to Editors
Halaven ^® (eribulin)
Eribulin is a non-taxane, microtubule dynamics inhibitor indicated for the
treatment of patients with breast cancer who have previously received at least
two chemotherapeutic regimens for metastatic disease and whose prior therapy
should have included an anthracycline and a taxane. ^[ ^2 ^] Eribulin belongs
to a class of antineoplastic agents, the halichondrins, which are natural
products, isolated from the marine sponge Halichondria okadai. It is believed
to work by inhibiting the growth phase of microtubule dynamics without
affecting the shortening phase and sequesters tubulin into non-productive
Halaven is approved in the European Union, USA, Russia, Switzerland, South
Korea, Japan, and Singapore. Halaven has received pricing authorisation and
has launched in Austria, Canada, Denmark, Finland, France, Germany, Iceland,
Italy, Luxembourg, Norway, Sweden, Switzerland, Slovenia, and the UK.
Global Phase III Study 301 ^
Study 301 was an open-labelled, randomised, two-parallel-arm, multicentre
study of Halaven (eribulin) versus capecitabine in 1,102 women with locally
advanced or metastatic breast cancer previously treated with anthracyclines
and taxanes, either in the (neo) adjuvant setting or for locally advanced or
metastatic disease. This study was outside of the licensed indication for
eribulin. Patients in the study received zero to two previous chemotherapies
for advanced disease.
Global Phase III Clinical Study 305 (EMBRACE) ^[ ^1 ^]
EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Treatment of
Physician's Choice (TPC) Versus Eribulin E7389) was an open-label, randomised,
global, multi-centre, parallel two-arm study designed to compare overall
survival in patients treated with eribulin versus a Treatment of Physician's
Choice (TPC) arm. TPC was defined as any single-agent chemotherapy, hormonal
treatment or biologic therapy approved for the treatment of cancer; or
palliative treatment or radiotherapy administered according to local practice.
The study included 762 patients with metastatic breast cancer who previously
had been treated with at least two and a maximum of five prior chemotherapies,
including an anthracycline and a taxane. The vast majority (96%) of patients
in the TPC arm received chemotherapy.
In the total Phase III EMBRACE study population, eribulin was shown to prolong
median overall survival in heavily pre-treated patients with metastatic breast
cancer compared to patients receiving TPC by 2.5 months compared to patients
receiving TPC (eribulin 13.1 months vs. TPC 10.6 months p=0.041). An updated
analysis, demonstrated a statistically significant improvement of 2.7 months
(13.2 vs 10.5 HR 0.81 (95% CI 0.067, 0.96) nominal p=0.014). A pre-planned
analysis of patients from Region 1 of the study (North America/Western
Europe/Australia) showed a significant overall survival benefit of eribulin
over TPC of 3.0 months (p=0.031).
The most commonly reported adverse reactions among patients treated with
eribulin in the EMBRACE study were fatigue (asthenia), a decrease in
infection-fighting white blood cells (neutropaenia), hair loss (alopecia),
numbness and tingling in arms and legs (peripheral neuropathy), nausea and
constipation. Peripheral neuropathy was the most common adverse event leading
to discontinuation from eribulin, occurring in less than 5% of the patients
involved in the EMBRACE trial. Neutropaenia only led to eribulin
discontinuation for 0.6% patients. Death due to serious side effects,
discontinuation and dose interruptions to treatment were lower in the eribulin
arm of the trial compared with the TPC arm.
Metastatic Breast Cancer
Over 300,000 women are diagnosed with breast cancer in Europe every year, of
whom about one third subsequently develop metastatic disease. ^ ^, ^
Metastatic disease is an advanced stage of the disease that occurs when cancer
spreads beyond the breast to other parts of the body.
Eisai in Oncology
Our commitment to meaningful progress in oncology research, built on
scientific expertise, is supported by a global capability to conduct discovery
and preclinical research, and develop small molecules, therapeutic vaccines,
and biologic and supportive care agents for cancer across multiple
Eisai is one of the world's leading research and development (R&D) based
Eisai concentrates its R&D activities in three key areas:
*Oncology including: anticancer therapies; tumour regression, tumour
suppression, antibodies, etc.
*Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight
*Vascular/Immunological reaction including: thrombocytopenia, rheumatoid
arthritis, psoriasis, inflammatory bowel disease
With operations in the U.S., Asia, Europe and its domestic home market of
Japan, Eisai employs more than 10,000 people worldwide. From its Knowledge
Centre in Hatfield, UK, Eisai has recently expanded its business operations to
include Europe, the Middle East, Africa and Russia (EMEA). Eisai EMEA has
sales and marketing operations in over 20 markets, including the United
Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria,
Denmark, Finland, Norway, Portugal, Czech Republic, Slovakia, the Netherlands,
Belgium, the Middle East and Russia.
For further information please visit our web site http://www.eisai.co.uk
1. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus
treatment of physician's choice in patients with metastatic breast cancer
(EMBRACE): a phase 3 open-label randomised study. The Lancet. 2011; 377:
2. SPC Halaven (updated November 2012). Available at:
http://www.medicines.org.uk/emc/medicine/24382 . Last accessed January 2013
3. Kaufman P, Awada A, Twelves C et al. A Phase III, open-label, randomised,
multicenter study of eribulin mesylate versus capecitabine in patients with
locally advanced or metastatic breast cancer previously treated with
anthracyclines and taxanes. Presented at 2012 CTRC-AACR San Antonio Breast
4. World Health Organization. Atlas of Health in Europe. 2003. World Health
Organization, Regional Office of Europe, Copenhagen, Denmark.
5. Cancer Research UK. Breast cancer incidence statistics.
]. Last accessed 03 December 2012.
Date of preparation: May 2013
Contact: Media Enquiries: Eisai Europe Ltd, Charlotte Andrews / Cressida
Robson, +44(0)7908-314-155, +44 (0)7947 231513, Cressida_Robson@eisai.net,
Charlotte_andrews@eisai.net; Tonic Life Communications, Siobhan Reilly / April
Kenneally, +44(0)207-798-9999 / +44(0)784-047-3199, +44(0)207-798-9263 /
+44(0)788-561-4274, firstname.lastname@example.org / email@example.com
Press spacebar to pause and continue. Press esc to stop.